Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis

Acta Diabetologica

Volumn 51, Issue 5, 2014, Pages 853-863

  Merlotti, Claudia ^a   Morabito, Alberto ^a   Ceriani, Valerio ^b   Pontiroli, Antonio E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Anti diabetic drugs; Bariatric surgery; Lifestyle modifications; Meta analysis; Obesity; Prevention; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BEZAFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; METFORMIN; PHENTERMINE PLUS TOPIRAMATE; TETRAHYDROLIPSTATIN;

ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; EVALUATION STUDY; HIGH RISK POPULATION; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PREVENTIVE MEDICINE;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; PREVENTIVE MEDICINE;

EID: 84919487349     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0624-9     Document Type: Article

References (56)

1. American Diabetes Association. Total prevalence of diabetes and pre-diabetes. American Association website. http://www.diabetes.org/diabetes-statistics/prevalence.jsp
2. Pi-Sunyer X (2009) The medical risk of obesity. Postgrad Med 121:21–33
3. Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444:881–887
4. Ford ES, Zhao G, Li C et al (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 55:1310–1317
5. Cheng YJ, Gregg EW, Geiss LS et al (2009) Association of HbA1c and fasting plasma glucose level with diabetic retinopathy prevalence in the U.S. population: implication for diabetes diagnostic thresholds. Diabetes Care 32:2027–2032
6. Ziegler D, Rathmann W, Dickhaus T et al (2008) Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Survey S2 and S3. Diabetes Care 31:464–469
7. CDC. Diabetes Fact Sheet online 2011. Jan 26.2011
8. American Diabetes Association (2012) Standards of medical care in diabetes-2012. Diabetes Care 35:S11–S63
9. Nathan DM, Davidson MB, DeFronzo RA et al (2007) Impaired fasting glucose and impaired glucose tolerance: implication for care. Diabetes Care 30:753–759
10. Brakis G, Stockert J, Molitch M et al (2009) Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 11:177–187
11. Progetto Cuore. Istituto Superiore di Sanità. http://www.cuore.iss.it/fattori/glicemia.asp. Accessed 13 June 2012
12. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321
13. Perrault L, Pan Q, Mather KJ et al (2012) Regression from pre-diabetes to normal glucose regulation is associated with long term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379:2243–2251
14. Phung OJ, Sood NA, Sill BE, Coleman CI (2011) Oral anti-diabetic drugs for the prevention of type 2 diabetes. Diabet Med 28:948–964
15. Knowler WC, Barrett-Connor E, Fowler SE, The Diabetes Prevention Program Research Group et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
16. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673–1679
17. Penn L, White M, Oldroyd J et al (2009) Prevention 006Ff type 2 diabetes in adults with impaired glucose tolerance: the European diabetes prevention RCT in newcastle upon Tyne UK. BMC Public Health 9:342
18. Penn L, White M, Lindstrom J, den Boer A et al (2013) Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of the European Diabetes Prevention Study RCT. PLoS One 8:e57143
19. Buchanan TA, Xiang AH, Peters RK et al (2002) Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high–risk Hispanic women. Diabetes 51:2796–2803
20. Chiasson JL, Josse RG, Gomis R (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077
21. Gerstein HC, Yusuf S, Bosch J, The Dream Trial Investigators et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105
22. Holman RR, Haffner SM, McMurray JJ, The NAVIGATOR Study Group et al (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1463–1476
23. DeFronzo RA, Tripathy D, Schwenke DC, The ACT NOW Study et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104–1115
24. Gerstein HC, Mohan V, Avezum A et al (2011) Long term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 54:487–495
25. Bosch J, Yusuf S, Gerstein HC, For the Dream Trial Investigators et al (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562
26. Mc Murray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490
27. Torgerson JS, Hauptman J, Boldrin MN et al (2004) XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155–161
28. Tenenbaum A, Motro M, Fisman EZ et al (2005) Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 26:2032–2038
29. Garvey T, Ryan DH, Henry R et al (2014) Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome with phentermine and topiramate extended-release. Diabetes Care 37:912–921
30. Long SD, O’Brien K, MacDonald KG et al (1994) Weight loss in severely obese subjects prevents progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 17:372–375
31. Pontiroli AE, Folli F, Paganelli M et al (2005) Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. A 4-year case-controlled study. Diabetes Care 28:2703–2709
32. Carlsson LM, Peltonen M, Ahlin S et al (2012) Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367:695–704
33. Yamaoka K, Tango T (2005) Efficacy of lifestyle education to prevent type 2 diabetes. A meta-analysis of randomized controlled trials. Diabetes Care 28:2780–2786
34. Norris SL, Zhang X, Avenell A et al (2005) Long term effectiveness of weight-loss interventions in adults with pre-diabetes. A review. Am J Prev Med 28:126–139
35. Lloret-Linares C, Greenfield JR, Czernichow S (2008) Effect of weight reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabet Med 25:1142–1150
36. Yates T, Khunti K, Bull F et al (2007) The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia 50:1116–1126
37. Anderson DC (2005) Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 39:102–109
38. Padwal R, Majumdar SR, Johnson JA et al (2005) A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28:736–744
39. Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr (2005) Angiotensin-Converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821–826
40. Andraws R, Brown DL (2007) Effect of inhibitors of the renin-angiotensin system on the development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99:1006–1012
41. Abuissa H, O’Keefe J (2008) The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab 10:1157–1166
42. Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews. Special topics in statistics: studies with more than two intervention groups. Wiley, Blackwell
43. Higgins JPT, Altman DG, Gotzsche PC, Juni P et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
44. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
45. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–180
46. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
47. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337:867–872
48. Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S (2007) Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 327:1–5
49. Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742
50. Scheen AJ (2007) Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes Metab 33:3–12
51. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122(248–256):e5
52. Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, O’Connor PJ, Theis MK, Campos GM, McCulloch D, Selby J (2013) A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23:93–102
53. Diabetes Prevention Program Research Group (2003) Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26:977–980
54. Pontiroli AE, Merlotti C, Veronelli A, Lombardi F (2013) Effect of weight loss on sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus hypocaloric diet. Acta Diabetol 50:843–850
55. Folini L, Veronelli A, Benetti A, Pozzato C, Cappelletti M, Masci E, Micheletto G, Pontiroli AE (2014) Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding. Acta Diabetol 51(3):361–368
56. Adams ST, Salhab M, Hussain ZI, Miller GV, Leveson SH (2013) Preoperatively determinable factors predictive of diabetes mellitus remission following Roux-en-Y gastric bypass: a review of the literature. Acta Diabetol 50:475–478